AnalystBook Research · Company Intelligence

OLYMPUS CORPORATION

7733.TTSE

Built from OLYMPUS CORPORATION's own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

The read at a glance

Computed from the FY2026 annual filing. Full history and the components behind each score are in the app.

  • Distress risk · Altman Z-Score 1.68 — grey zone — between safe and distressedWatch
  • Earnings-manipulation signal · Beneish M -2.38 — no flag raisedOK
  • Earnings quality 92/100 — accruals in line with cashOK

Where the revenue comes from

Fiscal 2026, as OLYMPUS CORPORATION reports it. History and quarterly detail are in the app.

  • Gastrointestinal solutions¥697.4B
  • Surgical and interventional solutions¥313.1B
  • Other¥208.0M
In the full recordFree for 14 days
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about OLYMPUS CORPORATION, every answer cited to the official filings🔒
  • The Intelligence Brief — added when OLYMPUS CORPORATION's brief passes our SEC-figure check🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.